Transgene Tasly (Tianjin) BioPharmaceutical is Pharmaceuticals in China that focus on oncolytic viral immunotherapy business. Founded in 2010. They cover business area such as manufacturer, immunotherapeutic product, biotechnology product, monoclonal antibody, development, inflammation, cancer, oncolytic viral immunotherapy, solid tumor, HBV therapeutic vaccine, HCV therapeutic vaccine.
2010
( 14 years old in 2024 )
Oncolytic Viral Immunotherapy
-
Tianjin
China
Private
manufacturerimmunotherapeutic productbiotechnology productmonoclonal antibodydevelopmentinflammationcanceroncolytic viral immunotherapysolid tumorHBV therapeutic vaccineHCV therapeutic vaccine
* We use standard office opening hours in near Transgene Tasly (Tianjin) BioPharmaceutical's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Transgene Tasly (Tianjin) BioPharmaceutical is Pharmaceuticals business from China that founded in 2010 (14 years old in 2024), Transgene Tasly (Tianjin) BioPharmaceutical business is focusing on Oncolytic Viral Immunotherapy.
Transgene Tasly (Tianjin) BioPharmaceutical headquarter office and corporate office address is located in Tianjin China.
Transgene Tasly (Tianjin) BioPharmaceutical was founded in China.
In 2024, Transgene Tasly (Tianjin) BioPharmaceutical is currently focus on oncolytic viral immunotherapy sector.
Above is snippet of Google Trends for "oncolytic viral immunotherapy" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Transgene Tasly (Tianjin) BioPharmaceutical, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
